Bolt Biotherapeutics, Inc. ( BOLT) Stock. Should you Buy or Sell? $ 1.77
-0.03 (-1.72 %)
Bolt Biotherapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | BOLT |
| Price | $1.77 |
| Beta | 0.000 |
| Volume Avg. | $220.72 thousand |
| Market Cap | $66.63 M |
| 52 Week Range | $1.39 - $17.07 |
Bolt Biotherapeutics, Inc. opened the day at $1.77 which is -1.72 % on yesterday's close. Bolt Biotherapeutics, Inc. has a 52 week high of $17.07 and 52 week low of $1.39, which is a difference of $15.68. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $66.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Bolt Biotherapeutics, Inc. for $66.63 M, it would take 15 years to get your money back. Bolt Biotherapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Bolt Biotherapeutics, Inc. Stock Forecast - Is Bolt Biotherapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Neutral | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.681 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -27.956 |
Valuing Bolt Biotherapeutics, Inc.
| Price Book Value Ratio | 0.317 | Price To Book Ratio | 0.317 |
| Price To Sales Ratio | 19.045 | Price Earnings Ratio | -0.681 |
How liquid is Bolt Biotherapeutics, Inc.
| Current Ratio | 9.734 |
| Quick Ratio | 9.469 |
Debt
| Debt Ratio | 0.201 | Debt Equity Ratio | 0.251 |
| Long Term Debt To Capitalization | 0.091 | Total Debt To Capitalization | 0.099 |
Latest news about Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m. ET (9:20 a.m. PT) in New York, New York.
Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet.
Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive said on Tuesday.
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -
Are these hot penny stocks on your list right now? The post Hot Penny Stocks to Watch Now?
About Bolt Biotherapeutics, Inc.
Description :
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
